Genentech Presents Promising Blood Disorder Data at ASH 2024
核心洞察
Genentech presented data at ASH 2024 highlighting advancements in lymphoma (搜索) treatment with Polivy, Lunsumio, and Columvi, showcasing durable remissions and overall survival benefits.
Five-year data from the Phase III POLARIX study showed a positive trend in overall survival for first-line diffuse large B-cell lymphoma (搜索) (DLBCL) patients treated with Polivy combination therapy.
Extended follow-up data from studies of Lunsumio and Columvi demonstrated long-lasting remissions and immune system recovery, supporting their use as fixed-duration bispecific antibodies.
Genentech, a member of the Roche Group, presented new data on its blood disorder treatments at the 66th American Society of Hematology (ASH) annual meeting in San Diego, California. The presentations, encompassing over 40 abstracts across nine blood disorders, underscored the company's commitment to improving patient outcomes in lymphoma (搜索). Key highlights included long-term follow-up data for Polivy, Lunsumio, and Columvi, as well as new investigational combination data.
Polivy Demonstrates Durable Remissions in DLBCL
Five-year data from the Phase III POLARIX study reinforced the potential of Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) to provide durable and lasting remissions for patients with first-line diffuse large B-cell lymphoma (搜索) (DLBCL). The study also showed a positive trend in overall survival (OS) in this patient population, representing a significant advancement in a disease area with limited progress in nearly two decades. The POLARIX study is a phase III, randomized, double-blind, placebo-controlled trial evaluating Polivy plus R-CHP versus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated DLBCL.
Lunsumio and Columvi Show Long-Lasting Remissions
Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio (mosunetuzumab) and the NP30179 study of Columvi (glofitamab) demonstrated long-lasting remissions and immune system recovery after the end of treatment. These findings support the use of fixed-duration bispecific antibodies for third-line or later follicular lymphoma (搜索) (FL) and DLBCL, respectively. These bispecific antibodies offer a targeted approach by engaging the patient's own immune cells to fight the cancer.
Subcutaneous Lunsumio Offers Improved Patient Experience
First presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal Phase II GO29781 study showed high rates of deep and durable responses and low rates and severity of cytokine release syndrome (CRS) in people with 3L+ FL. Subcutaneously administered Lunsumio could further improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy. The study aims to evaluate the safety, efficacy, and pharmacokinetics of subcutaneous mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (搜索).
Columvi Improves Quality of Life
New patient-reported outcomes data from the Phase III STARGLO study indicated comparable health-related quality of life between treatment arms, despite a higher median number of cycles received with the Columvi combination. Together with the significant improvement in OS observed in the study, these data support the potential benefit for patients with second-line or later DLBCL. The STARGLO study is a randomized, open-label, phase III study evaluating the efficacy and safety of glofitamab plus gemcitabine and oxaliplatin (GloFit-GemOx) versus rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation.